Compare DOUG & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | STXS |
|---|---|---|
| Founded | 1911 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 164.1M |
| IPO Year | 2021 | 2004 |
| Metric | DOUG | STXS |
|---|---|---|
| Price | $1.81 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 409.6K | ★ 530.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.24 |
| 52 Week High | $3.19 | $3.59 |
| Indicator | DOUG | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 45.56 |
| Support Level | $1.68 | $1.30 |
| Resistance Level | $1.84 | $1.51 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 21.43 | 28.12 |
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.